Global health & medicine最新文献

筛选
英文 中文
Suicide attempt and self-harm among hospitalized children in Japan: A nationwide inpatient database study. 日本住院儿童的自杀企图和自残:一项全国住院患者数据库研究。
IF 1.9
Global health & medicine Pub Date : 2024-12-31 DOI: 10.35772/ghm.2024.01052
Sachiko Kita, Kojiro Morita, Hideaki Watanabe, Nobuaki Michihata, Mayumi Morisaki, Noyuri Yamaji, Mari Ikeda, Hideo Yasunaga
{"title":"Suicide attempt and self-harm among hospitalized children in Japan: A nationwide inpatient database study.","authors":"Sachiko Kita, Kojiro Morita, Hideaki Watanabe, Nobuaki Michihata, Mayumi Morisaki, Noyuri Yamaji, Mari Ikeda, Hideo Yasunaga","doi":"10.35772/ghm.2024.01052","DOIUrl":"10.35772/ghm.2024.01052","url":null,"abstract":"<p><p>This study aims to delineate the characteristics and clinical trajectories of suicide attempts and self-harm, and its gender and age differences among children. This nationwide retrospective cross-sectional study utilized data extracted from the Japanese Diagnosis Procedure Combination inpatient database spanning 2016 to 2017. Children aged 7-17 years admitted to acute care hospitals for suicide attempts and self-harm, were identified. Patient characteristics included age, gender, suicide method, and comorbid psychiatric disorders. Trajectory information included the duration of hospital stay, admission ward, psychiatric/psychological interventions, in-hospital mortality, and healthcare expenditure. Data analysis encompassed 1,704 children hospitalized for suicide attempts and self-harm. Among these, 49.4% were junior high school age, 69.0% for female, and 28.4% for underweight. Overdose emerged as the most prevalent method for suicide attempts and self-harm (49.9%). Notably, 66.0% did not receive a diagnosis of any mental illness, and 56.3% did not undergo psychiatric/psychological care during their hospitalization. Boys were more likely to use high-lethality suicide methods, such as hanging (<i>p</i> < 0.001), and die during hospitalization (<i>p</i> < 0.001). Conversely, girls were more likely to use low-lethality suicide methods, such as drug overdose (<i>p</i> < 0.001), and receive psychiatric/psychological intervention during hospitalization (<i>p</i> = 0.015). Children aged 7-12 years were more likely to use high-lethality suicide methods, such as hanging (<i>p</i> < 0.001), and be diagnosed with attention-deficit/hyperactivity disorder (<i>p</i> < 0.001) and less likely to receive psychiatric/psychological intervention (<i>p</i> = 0.005) compared with other age groups. These findings suggest the importance of developing gender and age sensitive health policies, systems, and interventions to prevent child suicide.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"6 6","pages":"383-393"},"PeriodicalIF":1.9,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11680446/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142914222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Imaging of unicentric hyaline-vascular variant of Castleman disease: Emphasis on perilesional fat stranding and fatty proliferation. Castleman病单中心透明血管变异型的影像学:强调病灶周围脂肪搁浅和脂肪增生。
IF 1.9
Global health & medicine Pub Date : 2024-12-31 DOI: 10.35772/ghm.2024.01058
Sodai Hoshiai, Takeyuki Watadani, Shun Kagaya, Taishi Amano, Tomohiko Masumoto, Haruyasu Yamada, Izuru Matsuda, Ryota Matsuoka, Tetsuo Ushiku, Takahito Nakajima, Manabu Minami
{"title":"Imaging of unicentric hyaline-vascular variant of Castleman disease: Emphasis on perilesional fat stranding and fatty proliferation.","authors":"Sodai Hoshiai, Takeyuki Watadani, Shun Kagaya, Taishi Amano, Tomohiko Masumoto, Haruyasu Yamada, Izuru Matsuda, Ryota Matsuoka, Tetsuo Ushiku, Takahito Nakajima, Manabu Minami","doi":"10.35772/ghm.2024.01058","DOIUrl":"10.35772/ghm.2024.01058","url":null,"abstract":"<p><p>The hyaline-vascular variant of Castleman disease (HVCD) is relatively uncommon and demonstrates no specific clinical or laboratory findings; therefore, its preoperative diagnosis warrants a radiological evaluation. This study aimed to review imaging findings of HVCD, focusing on perilesional fat stranding and fatty proliferation. Patients with a pathologically confirmed HVCD diagnosis who had undergone CT were recruited from five hospitals from January 2000 to March 2023. Three experienced radiologists assessed CT findings, including lesion location, lesion size, calcification, enhanced pattern, feeding vessel visualization, and arterial enhancement. Perilesional fat stranding, fatty proliferation, neighboring fascial thickening, and surrounding lymphadenopathy were the primary targets of analysis. Moreover, the intensities and apparent diffusion coefficient (ADC) values on MRI and the maximum standardized uptake value (SUVmax) on <sup>18</sup>F-fluorodeoxyglucose positron emission tomography (PET) were evaluated. This study enrolled 43 patients (mean age 41.3 years ± 14.6 [standard deviation], 23 women). All lesions were well-defined round masses. Calcification and feeding vessels were detected in 21% (9/43) and 86% (36/43) of the patients, respectively. Perilesional fat stranding and fatty proliferation were observed in 44% (19/43) and 19% (8/43), respectively, with fatty proliferation detected only in retroperitoneal HVCD. Neighboring fascial thickening and surrounding lymphadenopathy were identified in 21% and 60%, respectively. The mean ADC value and SUVmax were 0.884 × 10<sup>-3</sup> mm<sup>2</sup>/s and 5.0, respectively. Retroperitoneal HVCD cases with perilesional fatty proliferation demonstrated a higher visceral fat ratio than those without (<i>p</i> = 0.046). Perilesional fat stranding and fatty proliferation were new characteristics of HVCD, especially in retroperitoneal cases.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"6 6","pages":"375-382"},"PeriodicalIF":1.9,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11680442/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142913958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Higher FIB-4 index at baseline predicts development of liver cancer in a community-based cohort with viral hepatitis. 基线较高的FIB-4指数可预测社区病毒性肝炎队列中肝癌的发展。
IF 1.9
Global health & medicine Pub Date : 2024-12-31 DOI: 10.35772/ghm.2024.01008
Makiko Kimura, Tomoki Nishikawa, Tetsuro Shimakami, Takeshi Terashima, Rika Horii, Masako Fukuda, Mika Yoshita, Noboru Takata, Tomoyuki Hayashi, Masaya Funaki, Kouki Nio, Hajime Takatori, Kuniaki Arai, Tatsuya Yamashita, Masao Honda, Junko Tanaka, Shuichi Kaneko, Taro Yamashita
{"title":"Higher FIB-4 index at baseline predicts development of liver cancer in a community-based cohort with viral hepatitis.","authors":"Makiko Kimura, Tomoki Nishikawa, Tetsuro Shimakami, Takeshi Terashima, Rika Horii, Masako Fukuda, Mika Yoshita, Noboru Takata, Tomoyuki Hayashi, Masaya Funaki, Kouki Nio, Hajime Takatori, Kuniaki Arai, Tatsuya Yamashita, Masao Honda, Junko Tanaka, Shuichi Kaneko, Taro Yamashita","doi":"10.35772/ghm.2024.01008","DOIUrl":"10.35772/ghm.2024.01008","url":null,"abstract":"<p><p>Hepatitis B and C (HBV and HCV) testing has been performed in Japan since 2002 and is subsidized by central and prefectural governments. A follow-up program for HBV- or HCV-infected persons was started at that time in Ishikawa Prefecture. This study analyzed the long-term follow-up data from this program. In total, 1029 participants in the Ishikawa Hepatitis Follow-up Program (HBV-infected, <i>n</i> = 535; HCV-infected, <i>n</i> = 494) were enrolled. Clinical data between the first visit and the most recent visit by March 2019 were collected. In the HBV-infected group, 384 persons (71.8%) were asymptomatic carriers, 133 (24.9%) developed chronic hepatitis, 15 (2.8%) developed compensated liver cirrhosis, and 3 (0.6%) developed decompensated liver cirrhosis. Ninety (16.8%) were treated with nucleotide/nucleoside analogs. Sixteen (3.0%) developed liver cancer. In the HCV-infected group, 427 persons (86.4%) developed chronic hepatitis, 46 (9.3%) developed compensated liver cirrhosis, and 21 (4.3%) developed decompensated liver cirrhosis. Forty-eight (9.7%) developed liver cancer. Three hundred and seventy-eight (76.5%) received antiviral therapy (a direct-acting antiviral in 166, interferon-based treatment followed by a direct-acting antiviral in 73, and interferon-based treatment in 139). The subsidy system was used by 270 persons (71.4%). Sustained virological response was confirmed in 340 persons (68.8%). A higher FIB-4 index at the first visit was a significant risk factor for liver cancer in HBV-infected and HCV-infected persons. The Ishikawa Hepatitis Follow-up Program has revealed the clinical course of HBV and HCV infection in community-dwelling individuals. The results will be used for micro-elimination at a prefectural level.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"6 6","pages":"404-415"},"PeriodicalIF":1.9,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11680450/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142914426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analysis of recent changes in treatment options for patients with hepatocellular carcinoma using data from a highly comprehensive Japanese national database: Impact of advances in systemic therapy and minimally invasive surgery. 利用高度综合的日本国家数据库的数据分析肝细胞癌患者治疗方案的最新变化:全身治疗和微创手术进展的影响。
IF 1.9
Global health & medicine Pub Date : 2024-12-31 DOI: 10.35772/ghm.2024.01061
Takashi Kokudo, Yasuhide Yamada, Takehiro Sugiyama, Rei Goto, Norihiro Kokudo
{"title":"Analysis of recent changes in treatment options for patients with hepatocellular carcinoma using data from a highly comprehensive Japanese national database: Impact of advances in systemic therapy and minimally invasive surgery.","authors":"Takashi Kokudo, Yasuhide Yamada, Takehiro Sugiyama, Rei Goto, Norihiro Kokudo","doi":"10.35772/ghm.2024.01061","DOIUrl":"10.35772/ghm.2024.01061","url":null,"abstract":"<p><p>In 2011, the Ministry of Health, Labour and Welfare started providing data from the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB) for research purposes. The NDB is an exhaustive and valuable database for health policymaking and research. It provides an accurate and most recent visualization of the burden of hepatocellular carcinoma (HCC) in Japan. In this study, we analyzed the trend in HCC treatments using data from the NDB. The NDB data were retrospectively analyzed to calculate the number of patients who were diagnosed with HCC (International Classification of Diseases, version 10 code of C22.0) and underwent treatment from fiscal year (FY) 2016 to 2020. We observed the following trends in HCC treatments during the past 5 years: a slight increase in the number of liver resection (LR) cases (+5.4%), a decrease in the number of radiofrequency ablation cases (-15.2%), and a considerable decrease in the number of transarterial chemoembolization/transarterial embolization cases (-38.2%). However, the number of patients who received systemic therapy dramatically increased from 471 in FY 2016 to 1,584 in FY 2020 (+236%). Among LR cases, there was a remarkable increase in the number of laparoscopic procedures from 1,227 in FY 2016 to 2,057 in FY 2020 (+67.6%). This analysis of a national highly comprehensive database revealed a very recent visualization of HCC management in Japan, wherein the impact of recent advances in systemic therapy and minimally invasive surgery was prominent.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"6 6","pages":"416-419"},"PeriodicalIF":1.9,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11680449/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142914411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advances in HIV management and challenges in Japan: Current situation of pre-exposure prophylaxis in Tokyo. 日本在艾滋病管理方面取得的进展和面临的挑战:东京暴露前预防的现状。
IF 1.9
Global health & medicine Pub Date : 2024-10-31 DOI: 10.35772/ghm.2024.01043
Daisuke Mizushima, Hiroyuki Gatanaga, Shinichi Oka
{"title":"Advances in HIV management and challenges in Japan: Current situation of pre-exposure prophylaxis in Tokyo.","authors":"Daisuke Mizushima, Hiroyuki Gatanaga, Shinichi Oka","doi":"10.35772/ghm.2024.01043","DOIUrl":"10.35772/ghm.2024.01043","url":null,"abstract":"<p><p>Since the world's first case series of human immunodeficiency virus (HIV) infection were reported, more than 40 decades have passed. The advancement of HIV treatment and prevention has progressed drastically. Especially, the efficacy of pre-exposure prophylaxis (PrEP) for HIV prevention has been proven by a number of trials and the number of new HIV cases has declined over the years due to the large-scale and rapid implementation of PrEP and universal HIV treatment in multiple countries. However, in Japan, PrEP is not approved or officially supported as of June 2024. Despite of the absence of top-down movement, men who have sex with men (MSM)-friendly private clinics initiated prescriptions of generic medicines for oral PrEP with necessary tests in Tokyo, which greatly contributed to improve access to PrEP. It is of note that current situation of bottom-up PrEP implementation using generic medicines in Tokyo is obviously cost-saving, which is needless to evaluate. However, expense of PrEP is fully out-of-pocket, which will hinder those with low or no income from accessing PrEP services despite the low prices of generic medicines. Furthermore, current PrEP implementation based on user-friendly clinics is functioning only in Tokyo. The role of public health authorities is important to solve these financial and geographical disparities in accessing PrEP services, without impairing existing virtues of accessibility and cost-saving in the current system.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"6 5","pages":"304-309"},"PeriodicalIF":1.9,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514633/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142557674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
State of the ART (antiretroviral therapy): Long-acting HIV-1 therapeutics. 抗逆转录病毒疗法(ART)现状:长效 HIV-1 疗法。
IF 1.9
Global health & medicine Pub Date : 2024-10-31 DOI: 10.35772/ghm.2024.01049
Shreya M Ravichandran, William M McFadden, Alexa A Snyder, Stefan G Sarafianos
{"title":"State of the ART (antiretroviral therapy): Long-acting HIV-1 therapeutics.","authors":"Shreya M Ravichandran, William M McFadden, Alexa A Snyder, Stefan G Sarafianos","doi":"10.35772/ghm.2024.01049","DOIUrl":"10.35772/ghm.2024.01049","url":null,"abstract":"<p><p>Human immunodeficiency virus (HIV) impacts millions of individuals worldwide, and well over 2/3 of those living with HIV are accessing antiviral therapies that are successfully repressing viral replication. Most often, HIV treatments and prevention are administered in the form of daily pills as combinations of multiple drugs. An emergent and effective strategy for suppressing viral replication is the application of long-acting antiretroviral therapy (LAART), or antivirals that require less-frequent, non-daily doses. Thus far, the repertoire of LAARTs includes the widely used antiviral classes of non-nucleoside reverse transcriptase inhibitors (NNRTIs) and integrase strand transfer inhibitors (INSTIs) and has recently expanded to include a capsid-targeting antiviral. Possible future additions are nucleoside reverse transcriptase inhibitors (NRTIs) and nucleoside reverse transcriptase translocation inhibitors (NRTTIs). Here, we discuss the different strategies of using long-acting compounds to treat or prevent HIV-1 infection by targeting reverse transcriptase, integrase, and capsid.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"6 5","pages":"285-294"},"PeriodicalIF":1.9,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514626/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142557680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploration of PrEP/PEP service delivery model in China: A pilot in eastern, central and western region. 中国 PrEP/PEP 服务提供模式的探索:在东部、中部和西部地区开展试点。
IF 1.9
Global health & medicine Pub Date : 2024-10-31 DOI: 10.35772/ghm.2024.01048
Zhen Jiang, Qi Wang, Jun Liang, Yuzhou Gu, Zhigang Han, Jie Li, Yake Xu, Youran Zhang, Xuehua Zhang, Jiahui Zhang, Jie Xu, Fan Lv
{"title":"Exploration of PrEP/PEP service delivery model in China: A pilot in eastern, central and western region.","authors":"Zhen Jiang, Qi Wang, Jun Liang, Yuzhou Gu, Zhigang Han, Jie Li, Yake Xu, Youran Zhang, Xuehua Zhang, Jiahui Zhang, Jie Xu, Fan Lv","doi":"10.35772/ghm.2024.01048","DOIUrl":"10.35772/ghm.2024.01048","url":null,"abstract":"<p><p>Since 2017, China has started a pilot exploration of pre-exposure prophylaxis (PrEP)/post-exposure prophylaxis (PEP) service aiming for human immunodeficiency virus (HIV) control. Efforts to summarize the pilot experience and sort out the gaps in service provision must be prioritized. In June-October, 2023, three provincial capital cities with two years of PrEP/PEP pilot experience in eastern, central and western China were chosen. A structural information collective tool was developed, as a framework to identify key links and steps in reviewing service procedures for PrEP/PEP service. Two main service models have been formed, including the independent offline service model led by professional health institutions and Multi-agencies (health institution/Community Based Organizations (CBOs)/Internet platform) online and offline collaborative service model. The pilot experience conceptualizes opportunities to integrate PrEP/PEP into HIV prevention efforts and, illustrates the optimizing path to move forward to reach for a high level HIV prevention and care continuum. Systematic barriers during the process of integration need to be noted and addressed. It is urgent to establish a realistic and feasible online and offline monitoring system to achieve a balance between standardized, safe, simplified and convenient services.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"6 5","pages":"295-303"},"PeriodicalIF":1.9,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514624/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142557677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sexual health care barriers and HIV/STI prevention for transgender people in Japan. 日本变性人的性保健障碍和 HIV/STI 预防。
IF 1.9
Global health & medicine Pub Date : 2024-10-31 DOI: 10.35772/ghm.2024.01045
Shin Ikebukuro, Daisuke Shiojiri, Hiroyuki Gatanaga
{"title":"Sexual health care barriers and HIV/STI prevention for transgender people in Japan.","authors":"Shin Ikebukuro, Daisuke Shiojiri, Hiroyuki Gatanaga","doi":"10.35772/ghm.2024.01045","DOIUrl":"10.35772/ghm.2024.01045","url":null,"abstract":"<p><p>Primary care and sexual health services for transgender people in Japan are lacking. We surveyed 233 transgender patients (57 [24.5%] assigned male at birth [AMABs] and 176 [75.5%] assigned female at birth [AFABs]) at the Personal Health Clinic to collect data on sexually transmitted infections (STI) and human immunodeficiency virus (HIV) risk, as well as lifestyle, stigma, and health literacy. Among respondents, 55% reported a sexual intercourse history, and 7.6% noted a previous STI. Only 62.2% underwent free STI testing. Current smoking rates were 19.3% higher in AFABs. Hospital visit hesitation was reported by 59.6%, and 83.3% experienced daily mental struggles. Awareness of post-exposure prophylaxis and pre-exposure prophylaxis was low. Our findings highlight the urgent need for improved primary care and sexual health services for transgender people in Japan, emphasizing the necessity to increase sexual health care facilities, reduce primary care access barriers, and improve knowledge among health care providers.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"6 5","pages":"352-356"},"PeriodicalIF":1.9,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514625/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142560332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analysis of tumor infiltrating immune cells in Kaposi sarcoma lesions discovers shifts in macrophage populations. 对卡波西肉瘤病变中肿瘤浸润免疫细胞的分析发现了巨噬细胞群的变化。
IF 1.9
Global health & medicine Pub Date : 2024-10-31 DOI: 10.35772/ghm.2024.01066
Takanobu Tagawa, Guruswamy Mahesh, Joseph M Ziegelbauer
{"title":"Analysis of tumor infiltrating immune cells in Kaposi sarcoma lesions discovers shifts in macrophage populations.","authors":"Takanobu Tagawa, Guruswamy Mahesh, Joseph M Ziegelbauer","doi":"10.35772/ghm.2024.01066","DOIUrl":"10.35772/ghm.2024.01066","url":null,"abstract":"<p><p>Limited information exists about the types of immune cells present in Kaposi sarcoma (KS) lesions, especially in KS in the gastrointestinal tract. Using previously reported RNA-sequencing results from Kaposi sarcoma lesions in skin and gastrointestinal tract with normal matched tissues from the same patients at the same time, we investigated changes in lymphocytes in these tissues. We employed a computational method that determines changes in cell type distributions using KS lesion transcriptome data compared to a reference set of RNA expression patterns of purified immune cells. Since secreted cytokines and chemokines from KSHV-infected cells may influence the microenvironment of Kaposi sarcoma lesions, we performed cytokine profiling of conditioned media from KSHV-infected primary human dermal lymphatic endothelial cells. We also measured how this conditioned media altered the differentiation of macrophages in cell culture assays. These results suggested that factors in conditioned media from KSHV-infected endothelial cells promoted differentiation of a promonocytic cell line to proinflammatory macrophages.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"6 5","pages":"310-315"},"PeriodicalIF":1.9,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514630/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142557675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting hypoxia-inducible factors in malignancies caused by Kaposis sarcoma associated herpesvirus. 针对卡氏肉瘤相关疱疹病毒引起的恶性肿瘤中的低氧诱导因子。
IF 1.9
Global health & medicine Pub Date : 2024-10-31 DOI: 10.35772/ghm.2024.01069
David A Davis, Prabha Shrestha, Robert Yarchoan
{"title":"Targeting hypoxia-inducible factors in malignancies caused by Kaposis sarcoma associated herpesvirus.","authors":"David A Davis, Prabha Shrestha, Robert Yarchoan","doi":"10.35772/ghm.2024.01069","DOIUrl":"10.35772/ghm.2024.01069","url":null,"abstract":"<p><p>In this editorial, we highlight the potential use of inhibitors of hypoxia-inducible factors (HIFs) for the use in Kaposi's sarcoma associated herpesvirus (KSHV) (also known as human herpesvirus-8) related malignancies. The past 20 years has accumulated detailed knowledge of the role of these factors in ensuring the maintenance of the KSHV in infected cells, in aiding the growth of the virus infected cells and aiding in the spread of virus from infected cells by inducing lytic reactivation. Today, a wide range of inhibitors for HIFs are currently being clinically evaluated for use in treating a variety of cancers. We discuss the current state of this research area as it relates to KSHV malignancies and describe pre-clinical and clinical evidence of drugs that target HIF to back up the idea that these inhibitors could be a novel way to treat KSHV related diseases.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"6 5","pages":"282-284"},"PeriodicalIF":1.9,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514629/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142557681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信